The company's ability to hold off generic competitors long enough to develop a pair of replacement drugs for Humira that are ...

A decade ago, AbbVie shareholders were hurtling toward a patent cliff—what the drug industry calls the sudden loss of sales exclusivity on a blockbuster. Since then, the stock has returned 460%, ...

AbbVie ABBV stock has risen 30.7% in the past six months compared with an increase of 8.9% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart ...

AbbVie (NYSE:ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for ...

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...

AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4. AbbVie beat estimates for both earnings and sales and also issued an upbeat ...

29 April 2024, Rhineland-Palatinate, Ludwigshafen: Malu Dreyer, Minister President of Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and ...

Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street ...